Each model starts with the factors that drive the company’s business. For a biotechnology developer, clinical milestones, eligible patient populations, launch timing, and net pricing can shape the forecast. For a mining company, production schedules, recoveries, capital spending, and commodity prices drive project economics. For technology and industrial businesses, we may focus instead on customer retention, order backlogs, or capacity utilization. We model costs and margins at the level supported by public disclosures.
We connect those assumptions to the income statement, balance sheet, and cash flow forecast. Capital expenditure and working capital are modeled alongside operations. Where funding is important, we estimate cash requirements and the possible effects of debt or new shares. Companies with similar earnings growth can have very different cash needs and outcomes for shareholders.
Valuation follows the forecasts. Depending on the business, we may use discounted cash flow, comparable-company multiples, project net asset value, or risk-adjusted valuation of drug programs. Sensitivities show how individual assumptions affect value, while scenarios test several changes together, such as a construction delay and the additional funding it could require.